{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:23:50Z","timestamp":1788391430946,"version":"build-2803163510"},"reference-count":23,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Radius Health, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>The ACTIVE study demonstrated the antifracture efficacy of abaloparatide in postmenopausal women with osteoporosis. ACTIVExtend demonstrated sustained fracture risk reduction with alendronate in abaloparatide-treated participants from ACTIVE. A direct comparison of the efficacy of abaloparatide and antiresorptive therapies has not been performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this analysis is to compare the antifracture efficacy of abaloparatide in ACTIVE with that of alendronate in ACTIVExtend.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>In this post hoc analysis, the rate of new vertebral fractures for women in ACTIVExtend (N = 1139) was calculated based on baseline and endpoint radiographs for placebo or abaloparatide in ACTIVE and alendronate in ACTIVExtend. Vertebral fracture rates between abaloparatide and alendronate were compared in a Poisson regression model. Fracture rates for nonvertebral and clinical fractures were compared based on a Poisson model during 18 months of abaloparatide or placebo treatment in ACTIVE and 18 months of alendronate treatment in ACTIVExtend.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The vertebral fracture rate was lower during abaloparatide treatment in ACTIVE (0.47 fractures\/100 patient-years) than alendronate treatment in ACTIVExtend (1.66 fractures\/100 patient-years) (relative risk reduction 71%; P = .027). Although the comparisons did not meet statistical significance, after switching from placebo (ACTIVE) to alendronate (ACTIVExtend), the rate of new vertebral fractures decreased from 2.49 to 1.66 fractures per 100 patient-years, and after switching from abaloparatide to alendronate from 0.47 to 0.19 fractures per 100 patient-years. The rates of nonvertebral fractures and clinical fractures were not significantly different.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Initial treatment with abaloparatide may result in greater vertebral fracture reduction compared with alendronate in postmenopausal women with osteoporosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgz162","type":"journal-article","created":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T05:44:06Z","timestamp":1572587046000},"page":"938-943","source":"Crossref","is-referenced-by-count":51,"title":["Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis"],"prefix":"10.1210","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2051-0505","authenticated-orcid":false,"given":"Benjamin Z","family":"Leder","sequence":"first","affiliation":[{"name":"Endocrinology Unit, Massachusetts General Hospital and Department of Medicine, Harvard Medical School, Boston, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Mitlak","sequence":"additional","affiliation":[{"name":"Radius Health, Inc, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-yi","family":"Hu","sequence":"additional","affiliation":[{"name":"Radius Health, Inc, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Hattersley","sequence":"additional","affiliation":[{"name":"Radius Health, Inc, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S","family":"Bockman","sequence":"additional","affiliation":[{"name":"Joan and Sanford Weill Medical College of Cornell University, Hospital for Special Surgery, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2019,11,1]]},"reference":[{"key":"2021122102013834600_CIT0001","author":"Office of the Surgeon General (US).","year":"2004"},{"issue":"Suppl 4","key":"2021122102013834600_CIT0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161435.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142016","volume":"22","author":"Camacho","year":"2016","journal-title":"Endocr Pract."},{"issue":"1","key":"2021122102013834600_CIT0003","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mayocp.2014.09.011","article-title":"Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States","volume":"90","author":"Singer","year":"2015","journal-title":"Mayo Clin Proc."},{"issue":"12","key":"2021122102013834600_CIT0004","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/1759720X17732562","article-title":"Critical issues and current challenges in osteoporosis and fracture prevention. An overview of unmet needs","volume":"9","author":"Lems","year":"2017","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"2021122102013834600_CIT0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.16.S3.1","article-title":"American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis","volume":"16(Suppl 3)","author":"Watts","year":"2010","journal-title":"Endocr Pract."},{"issue":"11","key":"2021122102013834600_CIT0006","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S2213-8587(17)30188-2","article-title":"Osteoporosis treatment: recent developments and ongoing challenges","volume":"5","author":"Khosla","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2021122102013834600_CIT0007","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3389\/fphar.2017.00803","article-title":"Pharmacological therapy of osteoporosis: a systematic current review of literature","volume":"8","author":"Pavone","year":"2017","journal-title":"Front Pharmacol."},{"issue":"9","key":"2021122102013834600_CIT0008","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra067395","article-title":"Mechanisms of anabolic therapies for osteoporosis","volume":"357","author":"Canalis","year":"2007","journal-title":"N Engl J Med."},{"issue":"1","key":"2021122102013834600_CIT0009","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling","volume":"157","author":"Hattersley","year":"2016","journal-title":"Endocrinology."},{"issue":"7","key":"2021122102013834600_CIT0010","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA."},{"issue":"8","key":"2021122102013834600_CIT0011","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"issue":"10117","key":"2021122102013834600_CIT0012","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet."},{"issue":"15","key":"2021122102013834600_CIT0013","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med."},{"issue":"2","key":"2021122102013834600_CIT0014","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","article-title":"Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial","volume":"92","author":"Cosman","year":"2017","journal-title":"Mayo Clin Proc."},{"issue":"2","key":"2021122102013834600_CIT0015","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1210\/jc.2013-3461","article-title":"The impact of nonhip nonvertebral fractures in elderly women and men","volume":"99","author":"Bliuc","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"2021122102013834600_CIT0016","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1007\/s00198-012-1935-8","article-title":"Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW)","volume":"23","author":"Roux","year":"2012","journal-title":"Osteoporos Int."},{"issue":"9041","key":"2021122102013834600_CIT0017","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet."},{"issue":"24","key":"2021122102013834600_CIT0018","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA."},{"issue":"4","key":"2021122102013834600_CIT0019","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1210\/jc.2015-4181","article-title":"Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA osteoporosis study","volume":"101","author":"Dempster","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"15","key":"2021122102013834600_CIT0020","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Intern Med."},{"issue":"9886","key":"2021122102013834600_CIT0021","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet."},{"issue":"8","key":"2021122102013834600_CIT0022","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00198-011-1856-y","article-title":"The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos Int."},{"issue":"20","key":"2021122102013834600_CIT0023","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgz162\/30340053\/dgz162.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/3\/938\/41823553\/jcem_105_3_938.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/3\/938\/41823553\/jcem_105_3_938.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T21:04:25Z","timestamp":1640034265000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/3\/938\/5610884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,1]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,11,1]]},"published-print":{"date-parts":[[2020,3,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgz162","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3]]},"published":{"date-parts":[[2019,11,1]]}}}